La Cross Clinical Products Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 03-07-2024
- Paid Up Capital ₹ 4.09 M
as on 03-07-2024
- Company Age 41 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 2.23 Cr
as on 03-07-2024
- Revenue 41.37%
(FY 2015)
- Profit 16.88%
(FY 2015)
- Ebitda -210.09%
(FY 2015)
- Net Worth -96.30%
(FY 2015)
- Total Assets -9.27%
(FY 2015)
About La Cross Clinical Products
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 4.09 M.
The company has closed loans amounting to ₹2.23 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Sudarsan Behera and Dinesh Gaonkar serve as directors at the Company.
- CIN/LLPIN
U24100MH1983PTC030043
- Company No.
030043
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 May 1983
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at La Cross Clinical Products?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sudarsan Behera  | Director | 18-May-2018 | Current |
| Dinesh Gaonkar | Director | 05-Apr-2011 | Current |
Financial Performance and Corporate Structure Insights of La Cross Clinical Products.
La Cross Clinical Products Pvt Ltd, for the financial year ended 2015, experienced significant growth in revenue, with a 41.37% increase. The company also saw a substantial improvement in profitability, with a 16.88% increase in profit. The company's net worth observed a substantial decline by a decrease of 96.3%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of La Cross Clinical Products?
In 2017, La Cross Clinical Products had a promoter holding of 99.82% and a public holding of 0.18%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Lalit Gas-Chem And Engineering Industries Private LimitedActive 41 years 8 monthsDinesh Gaonkar is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of Maharashtra Creation Date: 12 Jul 2012 | ₹3.38 M | Satisfied |
Bank Of Maharashtra Creation Date: 16 Mar 2011 | ₹2.40 M | Satisfied |
Others Creation Date: 03 Jul 2010 | ₹1.50 M | Satisfied |
How Many Employees Work at La Cross Clinical Products?
La Cross Clinical Products has a workforce of 1 employees as of Mar 27, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of La Cross Clinical Products, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped La Cross Clinical Products's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
